AAA      To change the font size

Use the 'View 'option in your browser and go to 'Text Size'

            

 

 
 
 

EORTC Trial 10041 (BIG 3-04) -     MINDACT

MINDACT (Microarray In Node-negative and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy)

A prospective randomized study comparing the 70-gene signature with the common clinical-pathological criteria in selecting patients for adjuvant chemotherapy in breast cancer with 0-3 positive nodes.

 

                                                   

1.Current Status of the trial

 
 

2. Mindact study outline and questionnaires for interested centers and coordinating centers/groups
 
 

 

 

1.Current status of the trial
 Countries in which the trial is activated

COUNTRIES

  Belgium

  The Netherlands

  Spain

  France

  Slovenia

  Germany

  United Kingdom

  Italy

  Switzerland

DATE OF ACTIVATION

  08/02/2007

  22/03/2007

  29/05/2007

  25/06/2007

  20/08/2007

  25/02/2008

  23/04/2008

  25/07/2008

  02/10/2008

  Total accrual (updated on 14/10/2009):

  Screening phase: 4114 patients

  Enrolled patients: 2264

Accrual information is released and updated every 6 months

 

2.MINDACT Study Outline and Questionnnaires

MINDACT study outline

A 5- page summary of the trial

MINDACT Center Facilities Questionnaire to be completed by all interested centers

If MINDACT is already open in your country, an amendment to the ethics committee is necessary to open new sites.

If you have any further questions or problems on filling in the questionnaire, please contact us at mindact@eortc.be

copyright and disclaimer

For comments - suggestions about the web site, send mail to Webmaster

Last update: 14 October 2009